Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

M. Linch,C. Ferrario,M. Stoeckle,B. Laguerre,J. A. Arranz Arija,T. Todenhofer,P. C. Fong,J. M. Piulats Rodriguez,W. Berry,U. Emmenegger,L. Mourey,N. Mar,L. J. Appleman,A. Joshua,H. J. Conter,X. T. Li,C. Schloss,C. H. Poehlein,J. S. de Bono,E. Y. Yu

ANNALS OF ONCOLOGY（2022）

Cited 0|Views7
No score
Abstract
Initial analysis of Cohort D of the phase 1b/2 KEYNOTE-365 (NCT02861573) study showed pembro + abi and prednisone had antitumor activity and acceptable safety in patients (pts) with chemotherapy-naive mCRPC. Two-year follow-up is presented.
More
Translated text
Key words
pembrolizumab,prostate cancer,prednisone,two-year,chemotherapy-naive,castration-resistant
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined